Drug Profile
NN 7129
Alternative Names: NN-7129; SC-la-FVIIa - Novo Nordisk; subcutaneous long-acting rFVIIa - Novo Nordisk; Subcutaneous N7-GPLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins; Serine endopeptidases
- Mechanism of Action Factor VIIa stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Haemophilia in Denmark (SC, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Haemophilia(In volunteers) in United Kingdom (SC, Injection)
- 31 Jul 2009 Phase-I clinical trials in Haemophilia in United Kingdom (SC)